Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Western Wealth Management LLC

Western Wealth Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 3.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,680 shares of the biopharmaceutical company’s stock after selling 1,094 shares during the quarter. Western Wealth Management LLC’s holdings in Pfizer were worth $914,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. Olistico Wealth LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at $25,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer during the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in Pfizer in the fourth quarter worth $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PFE. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. UBS Group upped their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Price Performance

NYSE PFE traded up $0.48 during trading on Monday, reaching $28.78. 6,859,646 shares of the company traded hands, compared to its average volume of 39,363,559. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.19. The company has a market cap of $163.08 billion, a price-to-earnings ratio of -478.67, a P/E/G ratio of 1.00 and a beta of 0.69. The stock’s 50 day moving average price is $28.75 and its two-hundred day moving average price is $27.91. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the prior year, the company posted $0.67 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.84%. Pfizer’s dividend payout ratio is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.